Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members.

[1]  Jan Sundquist,et al.  The Swedish Family‐Cancer Database 2009: prospects for histology‐specific and immigrant studies , 2010, International journal of cancer.

[2]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[3]  Peter C Albertsen,et al.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.

[4]  M. Barry,et al.  Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? , 2009, Journal of the National Cancer Institute.

[5]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[6]  John S. Witte,et al.  Prostate cancer genomics: towards a new understanding , 2009, Nature Reviews Genetics.

[7]  K. Hemminki,et al.  New cancer susceptibility loci: Population and familial risks , 2008, International journal of cancer.

[8]  K. Czene,et al.  Evaluation of bias in familial risk estimates: a study of common cancers using Swedish population-based registers. , 2008, Journal of the National Cancer Institute.

[9]  K. Hemminki,et al.  Concordance of survival in family members with prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Mona Shah,et al.  Family history of cancer and utilization of prostate, colorectal and skin cancer screening tests in U.S. men. , 2007, Preventive medicine.

[11]  W. Catalona,et al.  Characteristics of patients with familial versus sporadic prostate cancer. , 2006, The Journal of urology.

[12]  T. H. van der Kwast,et al.  Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. , 2006, The Journal of urology.

[13]  David Robinson,et al.  Survival in prostate carcinoma—Outcomes from a prospective, population‐based cohort of 8887 men with up to 15 years of follow‐up , 2005, Cancer.

[14]  K. Hemminki,et al.  Prostate cancer screening, changing age‐specific incidence trends and implications on familial risk , 2005, International journal of cancer.

[15]  K. Offit,et al.  Referral for cancer genetics consultation: a review and compilation of risk assessment criteria , 2004, Journal of Medical Genetics.

[16]  H. Ostrer,et al.  Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma , 2003, Cancer.

[17]  Henrik Grönberg,et al.  Prostate cancer epidemiology , 2003, The Lancet.

[18]  P. Stattin,et al.  Non‐systematic screening for prostate cancer in SwedenSurvey from the National Prostate Cancer Registry , 2003, Scandinavian journal of urology and nephrology.

[19]  K. Czene,et al.  Age specific and attributable risks of familial prostate carcinoma from the family‐cancer database , 2002, Cancer.

[20]  张哉根,et al.  Leu-M , 1991 .

[21]  O. Brawley,et al.  Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening , 2009, CA: a cancer journal for clinicians.

[22]  K. Hemminki,et al.  The nation-wide Swedish family-cancer database--updated structure and familial rates. , 2001, Acta oncologica.

[23]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .